Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells

Metformin exerts direct anti-tumor effects by activating AMP-activated protein kinase (AMPK), a major sensor of cellular metabolism in cancer cells. This, in turn, inhibits pro-survival mTOR signaling. Metformin has also been shown to disrupt complex 1 of the mitochondrial electron transport chain....

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Chukkapalli, Vineela, Gordon, Leo I., Venugopal, Parameswaran, Borgia, Jeffrey A., Karmali, Reem
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2018
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5940409/
https://ncbi.nlm.nih.gov/pubmed/29765528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24989
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares